• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Ardelyx (ARDX) Undervalued Following Its PM360 Trailblazer Awards?

    Simply Wall St·10/02/2026 18:28:35
    语音播报

    Ardelyx (ARDX) just picked up several honors at the 2026 PM360 Trailblazer Awards, including recognition for CEO Mike Raab and the IBSRELA marketing team. This has prompted fresh attention on the stock’s recent share performance.

    That recognition arrives during a rough patch for Ardelyx’s shares, with the 30-day share price return down 10.11% and the year-to-date share price return down 45.04%, even though the 5-year total shareholder return is up 166.14%. This points to long-term investors still being in positive territory despite fading recent momentum.

    Scan beyond Ardelyx and see how other under-pressure biopharma stocks with solid fundamentals are setting up on the 19 high quality undiscovered gems.

    Ardelyx now trades at a deep discount to analyst targets, despite recent awards and solid reported revenue growth. Is the market correctly pricing in risk, or is it leaving too much on the table?

    Most Popular Narrative: 74% Undervalued

    At a last close of $3.38 against a widely followed fair value estimate of $12.90, the Ardelyx valuation story is anchored in a view that future cash flows could justify a much higher price, supported by revenue and earnings forecasts that extend out to 2029.

    The rising prevalence of chronic kidney disease (CKD) and gastrointestinal disorders driven by an aging population continues to expand Ardelyx's core addressable markets, supporting sustained long-term demand for IBSRELA and XPHOZAH and driving future revenue growth. Recent and ongoing improvements in market access, prescription pull-through, and expansion of the sales force are boosting prescriber breadth and depth, contributing to accelerating product adoption and positioning the company to achieve strong topline growth and improved gross margins as fixed costs are leveraged.

    See why 73 investors see Ardelyx as 74% undervalued.

    Result: Fair Value of $12.90 (UNDERVALUED)

    Still, Ardelyx faces real pressure from its heavy dependence on IBSRELA and XPHOZAH, as well as from tighter payer controls that have already forced lower revenue guidance.

    Find out about the key risks to this Ardelyx narrative.

    Next Steps

    Sentiment around Ardelyx is clearly split, so treat this as your cue to move fast, review the data first hand, and weigh both the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Ardelyx?

    Do not stop your research with Ardelyx. Use the Simply Wall St screener to hunt for fresh ideas that fit your risk tolerance and return goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.